Monte Rosa Therapeutics, Inc.
GLUE · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $124M | $75.6M | +63.5% |
| Operating income | −$54.2M | −$81.1M | +33.2% |
| Net income | −$38.6M | −$72.7M | +46.9% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $54.4M | $12.8M | +325% |
| Operating income | −$1.90M | −$33.0M | +94.2% |
| Net income | $3.10M | −$27.1M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Monte Rosa's revenue in FY2025?
- $124M in FY2025 (Fiscal year ended Dec 31, 2025), +63.5% vs $75.6M a year earlier, per its 10-K filed Mar 2026.
- Was Monte Rosa profitable in FY2025?
- No: net income was −$38.6M and operating income −$54.2M in FY2025.
- What was Monte Rosa's revenue in Q3 2026?
- $54.4M (+325% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.